Sinopsis
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
Episodios
-
S3 Ep15: Rathore: What Biosimilar Developers Can Learn From Application Failures
26/07/2020 Duración: 07minTo learn more about the study, click here.
-
S3 Ep14: Byoungseo Choi on Celltrion's Biosimilar Goals For 2030
19/07/2020 Duración: 08minTo learn more about Celltrion Healthcare, visit celltrionhealthcare.com. You can learn more about the testing of Celltrion's infliximab biosimilar for the treatment of COVID-19 here.
-
S3 Ep13: Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization
12/07/2020 Duración: 04minTo learn more about Emory Healthcare, visit emoryhealthcare.org.
-
S3 Ep12: Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins
05/07/2020 Duración: 05minTo learn more about the study, read our full coverage of it here.
-
S3 Ep11: Joe Fuhr, PhD Discusses His Predictions for the Growing Biosimilar Market
28/06/2020 Duración: 03minThe United States’ slow start to biosimilar uptake has manifested in a number of ways, from delayed launches due to patent disputes to anticompetitive practices creating a distrust of biosimilars among patients and physicians. However, some experts still see hope for the industry. We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.
-
S3 Ep10: Nick Mitrokostas Discusses New Biosimilar Approval and Outlooks for 2020
21/06/2020 Duración: 05minTo learn more about the approval of Nyvepria, check out our article on it here. To learn more about Goodwin Proctor LLP, visit goodwinlaw.com/
-
S3 Ep9: Christine Simmon Discusses AAM Efforts for Biosimilar Legislation
14/06/2020 Duración: 06minTo learn more about AAM, visit accessiblemeds.org
-
S3 Ep8: Biosimilar Law Experts Discuss Potential Bills and Chances for Passage
07/06/2020 Duración: 15minTo learn more about Venable Fitzpatrick, visit venable.com. To learn more about all of the bills that were discussed, visit congress.gov
-
S3 Ep7: April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake
28/05/2020 Duración: 12minIt’s no secret that the US biosimilar industry has had a slow start in terms of uptake, but much of that setback is due to barriers caused by originator manufacturers taking advantage of current legislation. Although, the Hatch-Waxman Act and the Biologic Price Competition and Innovation Act (BPCIA) established pathways to approval for both generic drugs and biosimilars, there is still much legislative work to be done in order to truly reap the benefits of biosimilars. We sat down with April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential legislation such as The Hatch-Waxman Integrity Act and the Stop Stalling Act that would address barriers to biosimilar market entry.
-
S3 Ep6: Noelle Sunstrom and the Potential Growth for NeuClone
24/05/2020 Duración: 03minTo learn more about NeuClone, visit https://neuclone.com/
-
-
S3 Ep4: Dr. Sang-Jin Pak Talks Biosimilar Markets: US vs Europe
25/04/2020 Duración: 03minIn April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the first trastuzumab biosimilar in Europe. This earlier release of biosimilars in Europe is not an anomaly, as Europe has had a much easier time developing and launching biosimilars than the US thanks to their decade-long head start in the industry. We sat down with Dr. Sang-Jin Pak, the executive vice president of Samsung Bioepis’ Commercial Division to discuss the differences between the US and Europe.
-
S3 Ep3: "Not So Different": How the BPCIA Transition Will Impact Biosimilar Uptake
09/04/2020 Duración: 10minOn March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin products, to be approved under the biologics regulatory pathway. This week on the podcast, we’re speaking with executive director of the Biologics and biosimilars collective intelligence consortium (also known as the BBCIC) , Cate Lockhart, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how this new transition will impact the market and uptake efforts.
-
S3 Ep2: Employers Advocate for Lower Drug Costs Through Biosimilars
13/01/2020 Duración: 17minWith pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode, we speak with representatives of EmployersRX, a new coalition made up of 3 employer groups that are advocating for measures that would provide relief for the largest purchasers of healthcare.
-
S3 Ep1: Goodwin Attorneys Give a Look at Biosimilar Litigation
05/01/2020 Duración: 21minIn the past decade of experience with the the Biologics Price Competition and Innovation Act, a number of questions about the biosimilar pathway have been resolved through litigation. This week on the podcast, we're speaking with attorneys Robert Cerwinski, JD, and Alexandra Valenti, JD, both of whom are partners at Goodwin, about experience with litigation, the road ahead for biosimilars, and Goodwin's recently published guide to biosimilar litigation.
-
S2 Ep32: The Year in US Regulatory Activity for Biosimilars
29/12/2019 Duración: 06minWhen it comes to US biosimilars, 2019 was a busy year for regulatory activity. This week on the podcast, we're rounding up the key developments of the year.
-
S2 Ep31: At the American College of Rheumatology, a UK Perspective on Biosimilars
22/12/2019 Duración: 07minDuring the American College of Rheumatology’s recent 2019 annual meeting, we caught up with Paul Emery MD, FRCP, MA, FMedSci. Emery is the Versus Arthritis Professor of Rheumatology, University of Leeds, and the Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust in the United Kingdom. In this episode of the podcast, we’re sharing highlights of our interview with Emery about biosimilars.
-
S2 Ep30: AmerisourceBergen’s Sean McGowan Takes a Closer Look at US Biosimilar Launches
15/12/2019 Duración: 16minWith us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive, and tells us which developments he'll be watching closely in 2020.
-
S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab
08/12/2019 Duración: 10minLast month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.
-
S2 Ep28: Biosimilar Business Updates From the Month of November
01/12/2019 Duración: 08minThis week on the podcast, we’re rounding up the top biosimilar business stories of November 2019.